US · Healthcare · Medical Devices
EPS came in at 1.23 against a street estimate of 1.20 — a beat of 2.5%.
Analysts rate Globus Medical a buy (10 buy, 4 hold, 0 sell out of 14) with an average price target of $100.92.
CONFIDENT Q2 beat expectations with 6% reported revenue growth, 56% EPS growth, and 200bps margin expansion. Spine drove results; Nevro stabilizing. Company raised FY26 EPS guidance to $4.95-$5.05 vs. street $5.15. Q2 2026 International outpacing U.S. due to easier comps and deeper market penetration; some softness in Europe from strikes/heat waves noted but managed within expectations. Analysts pressed on international softness (competitors citing strikes/heat), U.S. Spine growth deceleration, and enabling tech transparency. Management countered with confidence in market health, easier back-half comps narrative, and long-term implant pull-through thesis underpinning flexible capital strategy. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.05% |
| Jupiter Topco LLC | 6.11% |
| Vanguard Capital Management, LLC | 3.80% |
| Vanguard Portfolio Management, LLC | 3.72% |
| Amvescap Plc. | 3.21% |
| Kayne Anderson Rudnick Investment Management LLC | 3.19% |
| State Street Corp | 2.77% |
| OZ Management LLC | 2.23% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $763,719 thousand, compared with $769,048 thousand in the third quarter of 2025. • Nine-month 2 | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 worldwide net sales were $763.7 million, down 0.7% year over year, or down 0.5% on a constant-currency basis. | 2026-11-05 |
| Quarterly report · Q2 2026 GLOBUS MEDICAL, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q2 2026: $789.6 million (up 6.0% vs. Q2 2025: $745.3 million) • Net sales s | 2026-08-06 |
| Results announced · Q3 2026 GLOBUS MEDICAL Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $789.6 million, up 5.9% year-over-year (5.6% constant currency) • GAAP N | 2026-08-06 |
| Board / officer change · Q2 2026 GLOBUS MEDICAL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • 1,000,000 additional shares authorized under 2021 Equity Incentive Plan as of June 3, 202 | 2026-06-04 |
| Quarterly report · Q1 2026 GLOBUS MEDICAL, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $759.9 million (Q1 2026) vs. $598.1 million (Q1 2025) — 27% year-over-year | 2026-05-07 |
| Results announced · Q2 2026 GLOBUS MEDICAL Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Worldwide net sales: $759.9 million, up 27.0% year-over-year (25.5% on constant currency b | 2026-05-07 |
| Proxy statement · Q2 2026 GLOBUS MEDICAL, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class II directors (Robert A. Douglas and Kei | 2026-04-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Share repurchase authorization increased by $500 million Globus Medical reported its sales and operating results for the three and nine months ended September 30, 2026, but the specific financial figures are not included in this 8-K text; investor | 2026-11-05 |
| Preliminary 2025 results and 2026 financial guidance provided Globus Medical, Inc. announced preliminary unaudited net sales results for Q4 2025 and the full fiscal year 2025 on January 7, 2026. The company also provided preliminary financial guidance | 2026-01-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Globus Medical — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.